Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer.
about
The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settingsSignificance of biological resource collection and tumor tissue bank creation.A primer on a hepatocellular carcinoma bioresource bank using the cancer genome atlas guidelines: practical issues and pitfalls.Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative explorationMolecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy.Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapySelective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis.Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality.Multidisciplinary management of resectable adenocarcinoma of the pancreatic head.Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resectionNeoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma.The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyInfluence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms.Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.Partnering to advance early detection and prevention efforts for pancreatic cancer: the Florida Pancreas Collaborative.Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors.Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.
P2860
Q27001144-B51E295E-EBD6-4D65-8BF2-827C1E8513EFQ33453292-02E6F53D-6231-4B13-873E-6F8A49C5357CQ33453324-C253888B-715F-4379-8CD6-D3C5FC2DFF46Q33531856-8F6E5890-C187-40B8-9945-2179668764A3Q33558951-BB4DAAFB-A521-479B-9375-AF9469D1AED0Q33590511-23F8A82C-0AE3-4B6E-BE9E-0BE0423A0124Q33860986-53FCEC3D-2B85-44C7-8967-D9D689850837Q33956574-6424581B-7501-4801-9345-DAB9584E7950Q34732306-F5A8B094-5F70-49CD-9E06-104FA26453FAQ36009614-A4C20093-3B94-4874-97D4-A4F0283384F1Q36063299-CDB1668C-4909-4894-AD09-0B3C78FF94FEQ36239183-901702DA-72CC-457E-93A0-273D299A5829Q36249120-654F8382-A490-4F97-8507-76300981CD7CQ37300020-9115F127-E842-423E-896F-9E09539A0A3AQ37449907-01D5CC3B-4DF2-424C-8D71-5BDAABB0A7C4Q37460276-122A9990-5838-48EF-BA0C-C5812DD2D663Q37461355-597A7B6C-799D-46BD-9E94-26CF7E690FC0Q37539690-3C01A6F0-4AE3-4A4A-85AB-CB8F7D60041CQ38998202-EC992FCD-429E-4B2A-A805-68CCE837C28EQ39430849-2A0A84AC-90CE-42C8-B71E-77EBDD089D61Q40470207-44306B5D-4B14-4AB3-9367-557091F52616Q41491695-9A8A057F-A190-46A0-9F03-CF4F81DFA8E9Q48136772-461CA0AA-E47A-4CD0-9DE3-50B4152F1E50Q48221354-07CDFFAE-E0B3-4961-9B5D-E9A1BF802649Q48630632-0E320624-C51B-4B9B-8CCC-89B1F5DE0A3EQ48642149-F2BAE7A5-D183-4715-8C11-9E0BF29D5EE3Q51442653-9B98562F-76D3-4CC9-9B71-42E3FA7EC039Q51751748-3DC11A87-946E-4F72-8BEF-83D3A0F2EA95Q51772050-DBED6F16-ACD3-4BBF-A928-358FE7234B8EQ51831319-5C2DCDE9-EDB8-4651-83BA-DBC16EAE77B4Q53027231-DF8F145A-4680-4FBE-A2A4-1B1FD0BEEFA6
P2860
Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Development of an integrated b ...... atabase for pancreatic cancer.
@ast
Development of an integrated b ...... atabase for pancreatic cancer.
@en
type
label
Development of an integrated b ...... atabase for pancreatic cancer.
@ast
Development of an integrated b ...... atabase for pancreatic cancer.
@en
prefLabel
Development of an integrated b ...... atabase for pancreatic cancer.
@ast
Development of an integrated b ...... atabase for pancreatic cancer.
@en
P2093
P1476
Development of an integrated b ...... atabase for pancreatic cancer.
@en
P2093
Axbal Lara
Douglas B Evans
Eric P Tamm
Henry Gomez
Huamin Wang
James L Abbruzzese
Jason B Fleming
Jeffrey H Lee
Nicole Sieffert
Peter W T Pisters
P2888
P304
P356
10.1245/S10434-008-9833-1
P577
2008-02-07T00:00:00Z
P6179
1048938567